Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Sponsor: Eisai Inc.
A PHASE2 clinical study on Estrogen Receptor-negative Breast Cancer and HER2-negative Breast Cancer, this trial is ongoing. The trial is conducted by Eisai Inc. and has accumulated 8 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Inc.
- Northwestern University
For direct contact, visit the study record on ClinicalTrials.gov .